Stockscreener 앱 받기
1.33
5.00%
-0.07
전일 마감가:
$1.40
열려 있는:
$1.4
하루 거래량:
77,666
Relative Volume:
0.44
시가총액:
$58.52M
수익:
-
순이익/손실:
$-31.39M
주가수익비율:
-1.5833
EPS:
-0.84
순현금흐름:
$-18.45M
1주 성능:
-5.67%
1개월 성능:
-16.35%
6개월 성능:
+101.52%
1년 성능:
+0.00%
1일 변동 폭
$1.31
$1.42
1주일 범위
$1.31
$1.54
52주 변동 폭
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
명칭
Quince Therapeutics Inc
전화
415-910-5717
주소
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
QNCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.33 | 58.52M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
D. Boral Capital Reaffirms “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Quince Therapeutics secures USPTO nod for A-T treatment patent By Investing.com - Investing.com Australia
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Earnings Coming in Better-Than-Expected As Peak Season Begins - The Globe and Mail
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average PT from Brokerages - Defense World
Earnings To Watch: Kirby (KEX) Reports Q4 Results Tomorrow - The Globe and Mail
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Marketscreener.com
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Consensus Target Price from Brokerages - MarketBeat
Quince's EryDex Shows Strong Safety Profile in Pediatric Ataxia-Telangiectasia Treatment - StockTitan
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Business Wire
Geode Capital Management LLC Purchases 66,170 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Average Target Price from Analysts - Defense World
Pharma Innovator Unlocks Multi-Disease Treatment Potential - Streetwise Reports
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Spotlight On US Penny Stocks For January 2025 - Simply Wall St
Research Analysts Offer Predictions for QNCX FY2024 Earnings - Defense World
Brokers Set Expectations for QNCX FY2024 Earnings - MarketBeat
Quince Therapeutics initiated with a Buy at Brookline - MSN
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Earns Buy Rating from Analysts at Brookline Capital Management - MarketBeat
Brookline initiates coverage on Quince Therapeutics shares, sees favorable risk-reward - Investing.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 23.8% in November - MarketBeat
QNCX (Quince Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Critical Survey: Amgen (NASDAQ:AMGN) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
QNCX stock touches 52-week high at $2.14 amid robust gains By Investing.com - Investing.com South Africa
Maxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
QNCX stock touches 52-week high at $2.14 amid robust gains - Investing.com
Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Rises By 23.0% - MarketBeat
QNCX Stock Soars to 52-Week High, Reaching $1.79 Amidst Strong Growth - Investing.com Australia
Quince Therapeutics regains Nasdaq compliance - Investing.com
Quince Therapeutics Inc (QNCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
0.33%
자본화:
|
볼륨(24시간):